Mining And Ores Tenders

Drugs with the Active Ingredient Ibuprofen (Atc: M01ae01 - in Sustained-Release Dosage Form with a Potency of 800 Mg)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V for the in Ii.2.4. Mentioned Active Ingredients with the Possibility of Conclusion Within the Framework of the So-Called Open-House Procedure.

Dynamic Procurement System for Food and Beverage Procurement

Open House Original Discount Contracts 2023-14 - Tafamidis (61Mg Strength and 20Mg Strength)

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Benralizumab, Atc Code: R03dx10 for the Period from 06/01/2023 to 05/31/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Filgrastin, Atc Code: L03aa02 for the Period from 06/01/2023 to 05/31/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Ethosuximide, Atc Code: N03ad01 for the Period from 06/01/2023 to 05/31/2025

Completion of a Non-Excl. Discount Agreement According to § 130A Paragraph 8 Sgb V for Follitropin Beta, Atc Code: G03ga06 for the Period from 06/01/2023 to 05/31/2025

Oh-Biologika-2023-08 Choriongonadotropin Alfa

Completion of a Non-Excl. Discount Agreement According to § 130C Paragraph 1 Sgb V for Dapagliflozin, Atc Code: A10bk01 for the Period from 06/01/2023 to 05/31/2025